
DISCO partners with Amgen to advance novel cancer therapies
Biopharmaceuticals company DISCO Pharmaceuticals has entered an exclusive license agreement with biotech company Amgen to advance novel cancer targeted therapies. The companies aim to develop the therapies for a target mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms… Read More

